Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Willy Hugo

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Nature Medicine|January 30, 2021
Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapyEva Pérez-Guijarro, Howard H Yang, Romina E Araya, et al.
Cancer Discovery|December 2, 2016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsDaniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, et al.
The Journal of Clinical Investigation|December 16, 2025
UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetesHo-Chung Chen, Madison F Bang, Hsing-Hui Wang, et al.
The New England Journal of Medicine|July 20, 2016
Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaJesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, et al.
Nature Medicine|February 12, 2019
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastomaTimothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, et al.
Frontiers in Oncology|January 22, 2019
The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous MelanomaXiaobei Zhao, Paul Little, Alan P Hoyle, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Nature Medicine|January 30, 2021
Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapyEva Pérez-Guijarro, Howard H Yang, Romina E Araya, et al.
Cancer Discovery|December 2, 2016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsDaniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, et al.
The Journal of Clinical Investigation|December 16, 2025
UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetesHo-Chung Chen, Madison F Bang, Hsing-Hui Wang, et al.
The New England Journal of Medicine|July 20, 2016
Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaJesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, et al.
Nature Medicine|February 12, 2019
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastomaTimothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, et al.
Frontiers in Oncology|January 22, 2019
The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous MelanomaXiaobei Zhao, Paul Little, Alan P Hoyle, et al.
Pageof 6